MAIA MAIA Biotechnology Inc
- Stocks
- Healthcare
- NYSEAMERICAN: MAIA
Price (delayed)
$1.13
Market cap
$37.28M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.57
Enterprise value
$27.14M
Relative Growth:
Rel. Growth:
17
Relative Strength:
Rel. Strength:
4
Relative Valuation:
Rel. Valuation:
N/A
Relative Profitability:
Rel. Profitability:
8
We are a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO, our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. In
Highlights
The EPS has surged by 65% year-on-year and by 28% since the previous quarter
MAIA Biotechnology's net income has increased by 42% YoY and by 18% from the previous quarter
MAIA's equity is up by 23% year-on-year but it is down by 22% since the previous quarter
MAIA Biotechnology's quick ratio has decreased by 39% YoY and by 7% from the previous quarter
Key stats
What are the main financial stats of MAIA
Market
Valuations
Earnings
Shares outstanding
32.99M
Market cap
$37.28M
Enterprise value
$27.14M
Price to earnings (P/E)
N/A
Price to book (P/B)
8.83
Price to sales (P/S)
N/A
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$19.78M
Net income
-$16.17M
EBIT
-$16.17M
EBITDA
-$16.17M
Free cash flow
-$15.77M
Per share
Balance sheet
Liquidity
EPS
-$0.57
EPS diluted
-$0.57
Free cash flow per share
-$0.52
Book value per share
$0.13
Revenue per share
$0
TBVPS
$0.36
Total assets
$11.05M
Total liabilities
$7.17M
Debt
$0
Equity
$3.88M
Working capital
$6M
Debt to equity
0
Current ratio
2.19
Quick ratio
2.01
Net debt/EBITDA
0.63
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-152.9%
Return on equity
-459.7%
Return on invested capital
N/A
Return on capital employed
-269.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MAIA stock price
How has the MAIA Biotechnology stock price performed over time
Intraday
2.73%
1 week
-13.08%
1 month
-34.68%
1 year
-63.07%
YTD
-42.93%
QTD
-26.62%
Financial performance
How have MAIA Biotechnology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$19.78M
Net income
-$16.17M
Gross margin
N/A
Net margin
N/A
MAIA Biotechnology's net income has increased by 42% YoY and by 18% from the previous quarter
MAIA Biotechnology's operating income has decreased by 7% from the previous quarter and by 3.6% YoY
Price vs fundamentals
How does MAIA's price correlate with its fundamentals
Growth
What is MAIA Biotechnology's growth rate over time
Valuation
What is MAIA Biotechnology stock price valuation
P/E
N/A
P/B
8.83
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 65% year-on-year and by 28% since the previous quarter
The stock's price to book (P/B) is 55% less than its last 4 quarters average of 19.6
MAIA's equity is up by 23% year-on-year but it is down by 22% since the previous quarter
Efficiency
How efficient is MAIA Biotechnology business performance
The company's return on equity has surged by 97% YoY and by 22% QoQ
The return on assets has surged by 52% year-on-year and by 16% since the previous quarter
Dividends
What is MAIA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MAIA.
Financial health
How did MAIA Biotechnology financials performed over time
MAIA's total assets is 54% greater than its total liabilities
MAIA Biotechnology's quick ratio has decreased by 39% YoY and by 7% from the previous quarter
The company's current ratio fell by 36% YoY and by 7% QoQ
The debt is 100% less than the equity
MAIA's equity is up by 23% year-on-year but it is down by 22% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.